
    
      Detailed Description : The study was conducted as an open-label, randomized, single-dose,
      2-way crossover, relative bioavailability study performed on 24 healthy adult male volunteers
      and 2 alternates. A total of 24 subjects completed the clinical phase of the study. In each
      period, subjects were housed from the evening before dosing until after the 36-hour blood
      draw. Single oral 3 mg doses were separated by a washout period of 7 days.
    
  